Document is current
Any future updates will be listed below
-
Authors
Da Silva, Ioana I. N. https://orcid.org/0000-0002-9486-2319
Ramirez, Desiree
Parylak, Sarah L.
Wallace, Leslie A.
Tucker, James K.
Erberich, Joel M.
Katariya, Rutvi
McDonald, Aidan H.
Gallina, Iryna S.
Tucker, Ariana L.
Burgado, Jillybeth
Jaeger, Baptiste N.
Barron, Jerika J. https://orcid.org/0000-0002-8983-3126
Pratt, Joshua M. https://orcid.org/0009-0005-6989-5855
Pena, Monique
Racha, Vipula
Lim, Christina K.
Fernandes, Sarah
Benassi, Simone
Randolph-Moore, Lynne
Vadodaria, Krishna C. https://orcid.org/0000-0002-3455-0209
Marchetto, Maria C.
Allen, Nicola J. https://orcid.org/0000-0002-7542-5930
Gage, Fred H. https://orcid.org/0000-0002-0938-4106
- License Information
-
More Information
Article History
Received: 15 August 2025
Accepted: 27 March 2026
First Online: 22 April 2026
Competing interests
: The authors declare the following competing interests: I.N.D., F.H.G., and J.K.T. retain shares in Talos Therapeutics, Inc. The Salk Institute for Biological Studies filed two patent applications for chemical matter and methods of use of CK2 inhibitors presented in this manuscript (PCT/US2021/032876 and PCT/US2023/080655; inventors: Ioana I Nitulescu, James Tucker, Fred H. Gage; status: ceased). The remaining authors declare no competing interests.
